Dr. Ferrante is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Adirondack Dr
East Greenwich, RI 02818- Is this information wrong?
Education & Training
- Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1991 - 1994
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1989 - 1991
- Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 1988 - 1989
- Georgetown University School of MedicineClass of 1988
- Providence CollegeBS, Cum Laude, 1980
Certifications & Licensure
- MA State Medical License 1993 - 2019
Awards, Honors, & Recognition
- Named Pharma Voice Top 100 Most Inspiring People 2012
- People Leader Award Pfizer, 2006
- Achievement Award Pfizer, 2005
- Join now to see all
Clinical Trials
- Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Galeterone Start of enrollment: 2016 Mar 01
Publications & Presentations
PubMed
- 33 citationsAndrogen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7...Mary-Ellen Taplin, Emmanuel S. Antonarakis, Karen J. Ferrante, Kerry Horgan, Brent A. Blumenstein, Fred Saad, Jun Luo, Johann S. de Bono> ;European Urology. 2019 Dec 1
- 55 citationsAndrogen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate CancerBruce Montgomery, Mario A. Eisenberger, Matthew Rettig, Franklin Chu, Roberto Pili, J. Stephenson, Nicholas J. Vogelzang, Alan J. Koletsky, Luke T. Nordquist, William ...> ;Clinical Cancer Research. 2016 Mar 15
- 7 citationsA phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors.Andre S. T. Planting, Ate van der Gaast, Patrick Schöffski, Michele Bartkowski, C. Verheij, Dennis Noe, Karen Jean Ferrante, Jaap Verweij> ;Cancer Chemotherapy and Pharmacology. 2005 Feb 1
- Join now to see all
Journal Articles
- Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate CancerMontgomery B, Eisenberger MA, Rettig MB, Chu FM, Pili R, Stephenson J, Vogelzang NJ, Koletsky AJ, Nordquist LT, Edenfield WJ, Mamlouk K, Ferrante KJ, Taplin, ME, Clin. Cancer Res, 1/2/2015
- A Phase 1 and Pharmacologic Study of the Matrix Metalloproteinase Inhibitor CP-471,358 in Patients with Advanced Solid TumorsPlanting A, van der Gaast A, Schoffski P, Bartkowski M, Verheij C, Noe D, Ferrante K, Verweij J, Cancer Chemotherapy and Pharmacology, 1/1/2005
- A Phase 1 Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant TumorsMoulder S, Mahany JJ, Lush R, Rocha-Lima C, Langevin M, Ferrante KJ, Bartkowski LM, Kajiji SM, Noe DA, Paillet S, Sullivan S, Clinical Cancer Research, 1/1/2004
- Join now to see all
Abstracts/Posters
- Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-re...Taplin ME, Antonarakis ES, Ferrante KJ, Horgan K, Blumenstein B, Saad F, Luo J, de Bono J, ASCO Annual Meeting, 1/1/2017
- Galeterone in Treatment-naive Patients with Castration-resistant Prostate Cancer with C-terminal Androgen Receptor Loss: Results from ARMOR2.Taplin ME, Chu F, Cochran J, Ferrante K, Lipsitz D, Roberts J, Sartor O, Heath E, ASCO Annual Meeting, 1/1/2016
- Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V...Antonarakis E, de Bono J, Ferrante K, Horgan K, Luo J, Saad F, Taplin ME, ASCO Annual Meeting, 1/1/2016
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: